Laboratory of Molecular Oncology
Laboratory of Molecular Oncology of National Center of Oncology was organized in 2014.The main direction of Laboratory is to conduct pharmacogenetic tests to increase the effectiveness of standard oncology treatment protocols and minimize toxicity of chemotherapy drugs.With this purpose, it is researched resistant mutation to gene drugs such as EGFR, KRAS, BRAF, PIK3A in tumor tissue.
Hereditarily transmitted allelic forms of UGT1A1 * 28 and DPYD * 2A gene which can give resistance to chemicals using in standard protocols are included to a list of test. The study of expression level of gene as RRM1, TUBB3, TYMS and ERCC1 involved in pharmacogenetics of some medications is aimed at improving the quality of treatment. One of the directions of the laboratory is the detection of transmissible hereditary mutations in these genes, as BRCA1/2, which is found in 60-80% of cases of malignant tumors of the breast and ovarian cancer. It provides a basis for preventive and predictive measures.
For the first time in our country, Laboratory of Molecular Oncology has been opened at the National Center of Oncology and each test conducted here is very important as information. The control of analyses performed in laboratory is conducted by engineers on standardization and certification. Conducting tests are performed by certified technical staff (medical assistant technician, laboratory assistant). The obtained results are analyzed by the biologist and geneticist, and transmitted to physicians.
